Anthony R. Bisconti

I'll research this attorney's professional background before drafting.

Let me verify the Regeneron case details and this attorney's background, since search results show a mixed practice profile.

Anthony R. Bisconti — Patent Litigation Practice Summary

Specialty / focus. Bisconti is not a career patent litigator; his tracked patent work is a single case, and it is in the biologics/BPCIA space rather than electronics, standards, or mechanical arts. Firm and directory profiles describe his practice as centered on bankruptcy and insolvency litigation, complex commercial and civil litigation, white-collar/government investigations, and appeals — not patent prosecution or IP litigation. His one tracked patent matter, Regeneron Pharmaceuticals, Inc. v. Amgen Inc., No. 2:24-cv-00264 (C.D. Cal.), is the Eylea®/aflibercept biosimilar case under 35 U.S.C. § 271(e) and the BPCIA, so his patent exposure is limited to life-sciences/biosimilar formulation disputes.

Side preference and role. Despite the "patent" label, his function in that case was not substantive patent advocacy: he served as California local counsel to Regeneron's out-of-state trial team (Williams & Connolly, Weil Gotshal, Kellogg Hansen) on the complaint, an ex parte scheduling application, and the JPML filings. The tracked record shows one appearance, and it is plaintiff-side (patent owner). One data point is not enough to establish a side preference; there is no tracked record of defending accused infringers or of representing NPEs/PAEs. Any inference that he "prosecutes for patent owners" should be drawn cautiously.

Firm context. He is a partner at Bienert Katzman Littrell Williams LLP (Los Angeles and San Clemente, California), and his filings date back to the firm's predecessor, Bienert, Miller & Katzman, PLC. Before private practice he clerked for the Hon. Maureen A. Tighe, U.S. Bankruptcy Court for the Central District of California. His appellate and Supreme Court work (e.g., the 2023 application in Clifton Capital Group matters) is bankruptcy/insolvency-related, not patent.

Notable case and outcomes. Regeneron v. Amgen is the only tracked patent matter. Regeneron filed it in C.D. Cal. in January 2024 asserting roughly 32 patents against Amgen's ABP 938 (Pavblu®); the case was transferred and consolidated into In re Aflibercept Patent Litigation, MDL No. 3103 (N.D. W. Va., Chief Judge Kleeh) in April 2024. Regeneron's motion for a preliminary injunction, limited to U.S. Patent No. 10,888,601 (the '865 patent), was denied, and that denial was affirmed on appeal to the Federal Circuit. Amgen then launched its biosimilar; Regeneron continued litigating remaining patents, including a later suit on a newly issued patent. Notably, no result has been reported in which Bisconti personally briefed or argued the substantive patent issues.

PTAB / IPR experience. None identified. Searches of PTAB records for the aflibercept proceedings show IPR activity by other counsel (e.g., Fish & Richardson for Mylan/Biocon and other biosimilar defendants); no IPR or PGR filings list Bisconti. On the available record, he should not be presented as having PTAB experience.

Bar / education. Admitted in California (SBN 269230) and New York; admitted in the C.D. Cal., S.D. Cal., and Ninth Circuit, and before the U.S. Supreme Court. J.D., Loyola Law School; B.A., UC Berkeley (per Best Lawyers and firm-adjacent directory profiles; the underlying State Bar record was not independently confirmed in this review).